Gossamer Bio (GOSS) Liabilities and Shareholders Equity (2018 - 2026)

Gossamer Bio's Liabilities and Shareholders Equity history runs 9 years deep, the most recent figure standing at $128.9 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 54.06% year-over-year to $128.9 million; the TTM figure through Mar 2026 stood at $750.9 million (down 43.12% YoY), while the FY2025 annual figure was $172.2 million, down 45.37% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $128.9 million, down from $172.2 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $373.4 million in Q2 2024, with the low at $128.9 million in Q1 2026.
• The 5-year median for Liabilities and Shareholders Equity is $272.4 million (2022), against an average of $266.4 million.
• The sharpest annual moves came in 2024 and 2026: Liabilities and Shareholders Equity soared 105.48% in 2024, then slumped 54.06% in 2026.
• Gossamer Bio's Liabilities and Shareholders Equity stood at $272.4 million in 2022, then climbed by 14.49% to $311.9 million in 2023, then rose by 1.08% to $315.3 million in 2024, then sank by 45.37% to $172.2 million in 2025, then slipped by 25.17% to $128.9 million in 2026.
• Business Quant data shows GOSS's Liabilities and Shareholders Equity at $128.9 million in Q1 2026, $172.2 million in Q4 2025, and $208.8 million in Q3 2025.